Monday Dec 2
Cell Therapeutics Receives $5 Million Milestone Payment for TRISENOXA
Cell Therapeutics, Inc. today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOX .
Tetralogic Pharmaceuticals IPO Is Not Logical For Investors
Tetralogic Pharmaceuticals Corp , a clinical-stage biopharmaceutical firm in the process of developing small molecule treatments for cancer, plans to raise $90.0 million in its upcoming IPO.
Just Released: "Sopherion Therapeutics, LLC - Pharmaceuticals &...
The company develops and commercializes anti-cancer agents. Its product includes Myocet, which is a non-pegylated liposomal doxorubicin.
Teva Opts for 5,000 Job Cuts as Big Acquisitions Flop
Teva Pharmaceutical Industries Ltd. became the world's largest generic-drug maker and highest-rated pharmaceutical stock earlier in the decade by spending more than $30 billion to acquire competitors.
Important Upcoming Catalyst For Antares - FDA Decision Expected October 14
At Stockmatusow , we've spent a lot of time in the past two years focusing on Antares Pharma and what they are working on.